Magle Group today announces that it has successfully completed its European medical device filing to extend the clinical use of EmboCept® S, the company's proprietary degradable starch microsphere (DS ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果